TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15262218

Group type: COMPARATOR
Intervention: Threatening words and images (TW)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Demanding cognitive load task (SR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exposure only (EO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral words and images (NW)
Number of subjects: 60
Study: 11369725

Group type: EXPERIMENTAL
Intervention: Alpha‐tocopherol supplementation group
Number of subjects: 14011

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 14011
Study: 9403477

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (INR 3.0‐4.5)
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Aspirin (30 mg daily)
Number of subjects: 1316
Study: 29200069

Group type: EXPERIMENTAL
Intervention: Real-time 3D visualization during trial 1
Number of subjects: 69

Group type: COMPARATOR
Intervention: Delayed visualization (playback of trial 2 before trial 3)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Real-time visualization and delayed visualization for the last trial
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mixed reality simulator training
Number of subjects: 69
Study: 27803391

Group type: EXPERIMENTAL
Intervention: Desmoteplase (90 μg/kg)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 23999733

Group type: EXPERIMENTAL
Intervention: Incredible Years basic parent training (IY)
Number of subjects: 52
Study: 22396085

Group type: EXPERIMENTAL
Intervention: Methadone (mean dose at delivery = 63.89 mg)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Buprenorphine (mean dose at delivery = 14.05 mg)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Nicotine consumption
Number of subjects: 117
Study: 19249432

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg orally twice a day before and on the day of coronary catheterization (n = 106)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Ascorbic acid 3 g and 2 g orally before, and 2 g twice after coronary catheterization with a 12-hour interval (n = 106)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in diabetic subgroup
Number of subjects: 212

Group type: COMPARATOR
Intervention: Ascorbic acid in diabetic subgroup
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in patients with high dose of dye
Number of subjects: 212

Group type: COMPARATOR
Intervention: Ascorbic acid in patients with high dose of dye
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Ascorbic acid
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) in diabetic patients
Number of subjects: 212

Group type: COMPARATOR
Intervention: Ascorbic acid in diabetic patients
Number of subjects: 212
Study: 16324889

Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) operating system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-post mixed-model ANCOVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random coefficients models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-stage pre-post mixed-model ANCOVA
Number of subjects: 0
Study: 15023582

Group type: EXPERIMENTAL
Intervention: Opiate addicts
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study: 11573660

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA) with remifentanil/propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balanced anaesthesia (BAL) with etomidate/fentanyl/isoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balanced anaesthesia (BAL)
Number of subjects: 40
Study: 9609981

Group type: EXPERIMENTAL
Intervention: Purified phenolic glycolipid (PGL‐1) ELISA in leprosy patients
Number of subjects: 698

Group type: COMPARATOR
Intervention: Purified phenolic glycolipid (PGL‐1) ELISA in non-leprosy cases
Number of subjects: 698
Study: 7923660

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study: 3246461

Group type: EXPERIMENTAL
Intervention: L-tryptophan supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30869958

Group type: EXPERIMENTAL
Intervention: Faking good
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Faking bad
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control condition (honest/honest)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Social desirability scales
Number of subjects: 233
Study: 27922194

Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pregabalin (200 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diphenhydramine (50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 25193374

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (iCBT)
Number of subjects: 110
Study: 23999454

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21454913

Group type: EXPERIMENTAL
Intervention: Swedish portion snus
Number of subjects: 14

Group type: COMPARATOR
Intervention: 4 mg nicotine polacrilex chewing gum
Number of subjects: 14
Study: 18266665

Group type: EXPERIMENTAL
Intervention: Methylphenidate (20 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17335542

Group type: EXPERIMENTAL
Intervention: Budesonide (1600 microg Pulmicort Turbohaler)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (Placebo Turbohaler)
Number of subjects: 10
Study: 14763919

Group type: EXPERIMENTAL
Intervention: Insulin-stimulated glucose uptake (ISGU) in FDR
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin-stimulated glucose uptake (ISGU) in controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue in FDR
Number of subjects: 20

Group type: COMPARATOR
Intervention: Visceral adipose tissue in controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VO2 max in FDR
Number of subjects: 20

Group type: COMPARATOR
Intervention: VO2 max in controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline palmitate appearance in FDR
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline palmitate appearance in controls
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 24 h u-cortisol/creatinine ratio in FDR
Number of subjects: 20

Group type: COMPARATOR
Intervention: 24 h u-cortisol/creatinine ratio in controls
Number of subjects: 20
Study: 11346340

Group type: EXPERIMENTAL
Intervention: Nonpalmoplantar pure epidermal sheet grafts (n = 14)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonpalmoplantar donor site skin grafts (n = 17)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Palmoplantar donor site skin grafts (n = 17)
Number of subjects: 48
Study: 9215845

Group type: EXPERIMENTAL
Intervention: EPO 150 U/kg three times a week
Number of subjects: 62

Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 62
Study: 7584276

Group type: EXPERIMENTAL
Intervention: Familiarity decision to familiar full names
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lexical decision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeating the same decision during initial and test phases
Number of subjects: 0
Study: 3667393

Group type: EXPERIMENTAL
Intervention: Female physicians
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Male physicians
Number of subjects: 112
Study: 31317322

Group type: EXPERIMENTAL
Intervention: smartphone‐enabled otoscope
Number of subjects: 60

Group type: COMPARATOR
Intervention: conventional otoscope
Number of subjects: 60
Study: 28846831

Group type: EXPERIMENTAL
Intervention: Cofact
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Beriplex
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cofact and Beriplex
Number of subjects: 15
Study: 26255511

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) intervention with stimulation of dense-disperse wave (10 Hz/50 Hz) at Tianshu (ST 25) and Zusanli (ST 36), 0.1 to 1.0 mA, once daily for 5 times a week for 2 weeks, then 2 times a week for 2 weeks.
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) intervention
Number of subjects: 340

Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 340
Study: 24015975

Group type: EXPERIMENTAL
Intervention: Ti (titanium) 4.1 mm diameter implants
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TiZr (titanium-zirconium) 3.3 mm diameter implants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both Ti and TiZr implants
Number of subjects: 40
Study: 21677073

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient beverage (250 mL/d including vitamin A, iron, and zinc)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Control beverage (isoenergetic)
Number of subjects: 566
Study: 19699832

Group type: EXPERIMENTAL
Intervention: Culturally adapted educational lessons based on the Medicine Wheel Model for Nutrition (6 lessons over 6 months)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual dietary education from personal providers
Number of subjects: 114
Study: 16125417

Group type: EXPERIMENTAL
Intervention: Motor Training (MT) alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Action Observation (AO) alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of Motor Training and Action Observation (MT + AO)
Number of subjects: 11
Study: 19780243

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy after concurrent chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor inhibitors (tyrosine kinase inhibitors or monoclonal antibodies)
Number of subjects: 0
Study: 11852812

Group type: EXPERIMENTAL
Intervention: Laser biostimulation (810 nm, 4 J/cm2)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (quasi-laserotherapy)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 49
Study: 9932083

Group type: COMPARATOR
Intervention: Irinotecan (350 mg/m2 administered over 90 minutes every 3 weeks)
Number of subjects: 539
Study: 8185450

Group type: EXPERIMENTAL
Intervention: High resistance exercise program
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal control subjects (CTL)
Number of subjects: 16
Study: 3063534

Group type: EXPERIMENTAL
Intervention: Rolipram 0.50 mg orally t.i.d. for the first three days, then 0.75 mg orally t.i.d. until day 28
Number of subjects: 0

Group type: COMPARATOR
Intervention: Desipramine 25 mg orally t.i.d. for the first three days, then 50 mg orally t.i.d. until day 28
Number of subjects: 0
Study: 31347193

Group type: EXPERIMENTAL
Intervention: Laser ablation (1.064 mm wavelength diode laser, 3.5 W output power, 1,100-1,500 J, 5-8 min/illumination, one or two fibers/session)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High-energy subgroup (n = 14, mean 599.9 ± 136.5 J/ml)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-energy subgroup (n = 7, mean 240.2 ± 74.6 J/ml)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (clinical follow up)
Number of subjects: 34
Study: 30818339

Group type: EXPERIMENTAL
Intervention: Maternal antiparasitic therapy during pregnancy
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: 10-valent S. pneumoniae conjugate vaccine and pentavalent vaccine
Number of subjects: 576
Study: 29634701

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.03%) eye ointment BD
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cyclosporine (0.05%) eyedrops QID
Number of subjects: 46
Study: 26912081

Group type: EXPERIMENTAL
Intervention: Self-reported service use
Number of subjects: 433
Study: 26492775

Group type: EXPERIMENTAL
Intervention: Heparin, propranolol with monopril and PCI
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Methylase (tenakteplaza) and propranolol, monopril followed by PCI after 1 day
Number of subjects: 63

Group type: COMPARATOR
Intervention: PCI only
Number of subjects: 63
Study: 22710021

Group type: EXPERIMENTAL
Intervention: High-dose statin
Number of subjects: 213

Group type: COMPARATOR
Intervention: Low-dose statin plus ezetimibe
Number of subjects: 213
Study: 19382492

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC) nasal packing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unpacked side (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CMC mesh
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CMC gel
Number of subjects: 40
Study: 17786889

Group type: EXPERIMENTAL
Intervention: Slow Stroke Massage
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 32
Study: 14980279

Group type: EXPERIMENTAL
Intervention: Postnatal dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled steroids used early (<2 wk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled steroids used late (>2 wk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study: 12513901

Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-administered therapy
Number of subjects: 0
Study: 9495601

Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg/day
Number of subjects: 281

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 281
Study: 7701064

Group type: EXPERIMENTAL
Intervention: Psychiatric patients with religious commitment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 44
Study: 2515967

Group type: EXPERIMENTAL
Intervention: 0.025 mg nitroglycerin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 356868

Group type: EXPERIMENTAL
Intervention: Phenelzine (in addition to diazepam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (in addition to diazepam)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0
Study: 30614468

Group type: EXPERIMENTAL
Intervention: Letrozole after aromatase inhibitor-based therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28935147

Group type: EXPERIMENTAL
Intervention: Resistant wheat starch (RWS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard wheat flour (SWF)
Number of subjects: 27
Study: 26194634

Group type: EXPERIMENTAL
Intervention: Corneal cross-linking treatment (15 eyes)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (14 eyes)
Number of subjects: 29
Study: 22963506

Group type: EXPERIMENTAL
Intervention: Spironolactone 12.5 mg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5 mg and 25 mg)
Number of subjects: 186
Study: 22157475

Group type: EXPERIMENTAL
Intervention: Transradial (TR) approach
Number of subjects: 3340

Group type: COMPARATOR
Intervention: Transfemoral (TF) approach
Number of subjects: 3340
Study: 19558610

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg twice daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg twice daily) in statin users (n = 22)
Number of subjects: 100
Study: 16741303

Group type: EXPERIMENTAL
Intervention: Image-derived input functions (IDIFs) from the ascending aorta
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Image-derived input functions (IDIFs) from the left ventricle
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Image-derived input functions (IDIFs) from the abdominal aorta
Number of subjects: 76
Study: 15636668

Group type: EXPERIMENTAL
Intervention: Tolterodine combined with an educational intervention (printed information and explanation about OAB, medication use, and behavioral treatments)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolterodine alone (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolterodine combined with an educational intervention
Number of subjects: 0
Study: 11387573

Group type: EXPERIMENTAL
Intervention: Electric stimulation through a microcomputer every night for 8 hours.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group using identical functioning units that delivered no current.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electric stimulation (compliant patients).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electric stimulation (noncompliant patients).
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (compliant patients).
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (noncompliant patients).
Number of subjects: 40
Study: 9404828

Group type: EXPERIMENTAL
Intervention: Heparin-induced extracorporeal low-density lipoprotein (LDL) precipitation (HELP)
Number of subjects: 0
Study: 8121866

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Flumazenil and Placebo
Number of subjects: 40
Study: 3465581

Group type: EXPERIMENTAL
Intervention: Prednisolone 40 mg/day
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 1500 ug/day
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 29659529

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study: 27727055

Group type: EXPERIMENTAL
Intervention: Immediate motion (IM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed motion (DM)
Number of subjects: 60
Study: 24177413

Group type: EXPERIMENTAL
Intervention: Standard clinical advice plus free-of-charge access to a group-based adaption of the DPP offered by the YMCA
Number of subjects: 509

Group type: COMPARATOR
Intervention: Standard clinical advice alone
Number of subjects: 509
Study: 23091246

Group type: EXPERIMENTAL
Intervention: TRA-8 alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TRA-8 + Abraxane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Abraxane (paclitaxel) alone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 15833948

Group type: EXPERIMENTAL
Intervention: Exercise intervention (≥ 45 minutes of moderate-intensity aerobic activity 5 days/week)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 173
Study: 12015810

Group type: EXPERIMENTAL
Intervention: Active participation in musical activity (30-minute session playing percussive instruments and singing)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Passive participation in musical activity (30-minute session listening to live music)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 33
Study: 10624252

Group type: EXPERIMENTAL
Intervention: Nursing home care settings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community hospital care settings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients on hypnotic medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients not on hypnotic medication
Number of subjects: 0
Study: 7793870

Group type: EXPERIMENTAL
Intervention: LYO (lyophilized RSVIG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LYO-VI (lyophilized RSVIG with viral inactivation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: LIQ-VI (liquid RSVIG with viral inactivation)
Number of subjects: 30
Study: 2162239

Group type: EXPERIMENTAL
Intervention: Etoposide (120 mg/m2, days 1‐3)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Etoposide plus high-dose cisplatin (60 mg/m2, days 1‐2)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Etoposide
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Etoposide plus high-dose cisplatin
Number of subjects: 216
Study: 469108

Group type: EXPERIMENTAL
Intervention: Caffeine (low dose equivalent to one cup of coffee)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Caffeine (high dose equivalent to three cups of coffee)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29869961

Group type: EXPERIMENTAL
Intervention: Digital Mammography plus Digital Breast Tomosynthesis (DBT+DM)
Number of subjects: 19560

Group type: COMPARATOR
Intervention: Digital Mammography (DM)
Number of subjects: 19560
Study: 28468749

Group type: EXPERIMENTAL
Intervention: EDGE (digital health system)
Number of subjects: 166
Study: 25731582

Group type: EXPERIMENTAL
Intervention: Phonak BTE with NLFC
Number of subjects: 11

Group type: COMPARATOR
Intervention: Phonak BTE without NLFC
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oticon BTE with wideband response
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NLFC condition
Number of subjects: 11
Study: 23168228

Group type: EXPERIMENTAL
Intervention: Sequential therapy (SQ group): PPI + amoxicillin for 5 days followed by PPI + clarithromycin + metronidazole for 5 days
Number of subjects: 323

Group type: COMPARATOR
Intervention: Standard triple therapy (AM group): PPI + amoxicillin + metronidazole for 7 days
Number of subjects: 323

Group type: COMPARATOR
Intervention: Standard triple therapy (AC group): PPI + amoxicillin + clarithromycin for 7 days
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Sequential therapy (SQ group)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Standard triple therapy (AM group)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Standard triple therapy (AC group)
Number of subjects: 323